$1.26
-0.04 (-3.08%)
Open$1.30
Previous Close$1.30
Day High$1.33
Day Low$1.24
52W High$34.75
52W Low$0.96
Volume—
Avg Volume896.2K
Market Cap3.64M
P/E Ratio—
EPS$-30.28
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,223.0% upside
Current
$1.26
$1.26
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.51M | 586.6K | 551.3K |
| Net Income | -64,780,547 | -23,280 | -22,798 |
| Profit Margin | -862.3% | -4.0% | -4.1% |
| EBITDA | -65,099,019 | -32,929 | -31,435 |
| Free Cash Flow | — | -20,426 | -16,844 |
| Rev Growth | +212.6% | +23.9% | +11.9% |
| Debt/Equity | — | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |